Innovation
Extend
The bioreactor systems produced by Hybrid Organ are based on recent scientific
developments, which have opened up new areas of operation in biomedicine.
They allow a broad clinical applicability in intensive care medicine and
offer a basis in medical biotechnology for other substance producing technologies
via primary cells. New market segments with high market potential have opened
up. A change of paradigm has already been generated by the MELS (Modular
Extracorporeal Liver System).
A sustainable competitive advantage can be achieved through innovative bioreactor
developments with various unique selling positions, USPs.
Unique Selling Positions
In vitro tissue culture has been based almost solely on the cultivation
of cell monolayers on cell culture vessels. Although conventional cultures
are easy to handle and can be managed at low expenditure, the in vitro simulation
of organ like conditions is not sufficient: it is the lack of three-dimensional
structures and of physiological cell matrix interactions that direct the
cell metabolism and gene expression towards a differentiated state.
The Hybrid Organ bioreactors address these problems and enable co-culturing
of different cell populations at a higher density and in 3D formation of
organ-like cell aggregations. They also allow the cells to produce bio-matrix
in the neo-tissues. The unique architecture of the bioreactors, coupled
with the options of decentralized medium perfusion, nutrient and metabolite
exchange with low gradients, and efficient integrated oxygenation make this
possible. |